Pharmacological Aspects of Statins Are Relevant to Their Structural and Physicochemical Properties

Zeina Althanoon1, Ibrahim M Faisal2, Abdulla A Ahmad1, Marwan M. Merkhan3

1College of Pharmacy, University of Mosul, Mosul, Iraq.
2College of Medicine, University of Mosul, Mosul, Iraq.

Correspondence:
Marwan M Merkhan, PhD Pharmacology
Department of Pharmacology and Toxicology.
College of pharmacy, University of Mosul, Mosul, Iraq.
e-mail: marwanmerkhan@uomosul.edu.iq

ABSTRACT
Statins are group of hypolipidemic agents that are effective at lowering blood lipid levels subsequently improving ischemia associated pathology of atherosclerosis. This beneficial effect jointly linked to the members of statin and the miscellaneous effects they produce which is distinctly present with some statins but not others. These lipid lowering agents differ structurally and physically resulting in two group based on their hydrophobicity. Since, lipophilic penetrate readily across cell membrane, hydrophilic potentially needs a carrier and their volume of distribution is lower comparative to lipophilic statins. These structural and physicochemical variation ultimately result in variation in pharmacokinetic properties and could potentially carry an impact on their pharmacodynamics and the outcome of the therapeutic course. Moreover, variation in these properties could lead to repurposing of statin for new indications in the future.

Keywords: Statin, Hydrophilic, Lipophilic, Pharmacokinetic, Pharmacodynamic.

Correspondence:
Marwan M. Merkhan
PhD Pharmacology
Department of Pharmacology and Toxicology.
College of pharmacy, University of Mosul, Mosul, Iraq.
e-mail: marwanmerkhan@uomosul.edu.iq
mobile: 009647508662343

INTRODUCTION
Lipid lowering drugs have shown to reduce the ischemic heart disease (IHD) both in patients with hyperlipidaemia and those with normal LDL-C levels. Therefore, it has been recommended to introduce some dietary changes to reduce the cholesterol level (particularly LDL-C). Various classes of medication have been introduced as hypolipidemic agents including: nicotinic acid, fibrates, cholesteryl absorption inhibitors and more recently the statins, the latter are the most commonly prescribed lipid-reducing therapies. The mechanism of action of statins is based on blocking the committed step in the synthesis of cholesterol; recently called the mevalonate pathway. Additionally, statins upregulate HDL-C and decrease triglyceride levels. Moreover, statin exert its lipid-modifying effects through inhibition of apolipoprotein-B100 biosynthesis and reduction in biosynthesis of triglyceride-rich lipoproteins in liver.

Apart from their lipid-modifying effects, statins characterized by its pleiotropic effects through exerting a beneficial cardiovascular effects. These newly discovered actions has been attributed to their inhibitory role in biosynthesis of non-steroidal isoprenoid compounds, an intermediary product of mevalonate pathway. Statin pleiotropic effects include inhibition of inflammatory response, stimulation of repair endothelial cell injury and inhibition of smooth muscle cell proliferation. Large clinical studies reported that statins reduced the morbidity and mortality rate in patients with or without IHD. Moreover, statins have been shown to reduced progression and even encourage regression of coronary atherosclerosis, resulting in reduction in percentage of new ischemic injury and subsequently coronary occlusion in comparison to statin-untreated patients. This effect has been attributed to the reduction in the core of atherosclerotic plaque resulting in prevention of plaque rupture that would initiate intramural hemorrhage/thrombosis. This review article aimed at explaining the link between the differences between statins pharmacokinetics and pharmacodynamics and its correlation to structural and physicochemical properties.

Diversity of statin structures
Source of statins
fungal derived statins include: lovastatin, pravastatin, and simvastatin, while synthetic statin include; atorvastatin, cerivastatin, fluvastatin, pravastatin, pitavastatin, and rosuvastatin.

Structure of statins
the chemical structure of each is outlined below (see Figure 1). The principle parts of structure are three basic units; the analogue of HMG-CoA which is the target enzyme substrate and a side chain ring structure that determines their physical properties especially their solubility and pharmacokinetic and the third part is the complex ring structure which is involved in binding of statin molecule to the HMG-CoA reductase enzyme (see Figure 1).
Physicochemical properties of statins

Some statins are lipophilic, including lovastatin, atorvastatin, simvastatin, and fluvastatin, while both rosvastatin and pravastatin are hydrophilic because they carry a methane-sulphonamide moiety and hydroxyl moiety, respectively. The mechanism of statins is based on binding of the molecules to the active site of the enzyme, thereby preventing the substrate from binding and therefore inhibiting the subsequent steps of cholesterol biosynthesis. The structural crystallography of statin-enzyme complex revealed that rosvastatin has supra-binding through hydrogen bonding coupled with the polar interaction unique to the rosvastatin; these variation could explain the dominant pleiotropic activities of certain statins in comparison to others.

Diversity of statin pharmacokinetics

Administration and Absorption

Following oral administration of simvastatin and lovastatin as a lactone-prodrug; they undergo enzymatic hydrolysis into active form, hydroxyl acid active form, while other statins are administered as an active as such i.e. they are already hydroxyl acid active form. Following administration, the absorption is rapid reaching peak plasma level (T_{max}) in approximately 4 hours. The time of administration during the day of rosvastatin have no effect on pharmacokinetic of rosvastatin whereas atorvastatin pharmacokinetics were affected accordingly; nevertheless, their pharmacodynamics is the same regardless to their administration time. This variation could be explained by their longer duration of action than other statins (<3 hours); hence, they are favorably administered on evening to interfere with peak hepatic cholesterol synthesis.

Bioavailability and half-life

The clearance half-life of atorvastatin is up to 14 hours; this long elimination time is responsible about the extended lipid-lowering effects of atorvastatin compared to other statins. Additionally, the lipid-lowering efficacy is further extended by atorvastatin active metabolite. The elimination half-life is 19 hours for rosvastatin and 11 hours for pitavastatin. The commercially available statins characterized by massive first-pass effect and thereby low bioavailability. The bioavailability of pitavastatin is higher (up to 80%) than cerivastatin (up to 60%). Liver: being the target organ for metabolism of statin, first-pass effects determine the effect of statins. Statin absorption affected by food at various degree, food...
improves the absorption of lovastatin and impairs the absorption of is best absorbed with food atorvastatin, fluvastatin, and pravastatin where food has no effects on simvastatin or rosuvastatin; nevertheless, hypolipidaemic efficacy of statins are not affected by the weather the drug were administered with the dinner or at bedtime. Apart from pravastatin, the plasma protein binding capacity of statins is extensive resulting in low free form of the drug. Despite of high circulating free form of pravastatins and rosuvastatin compared to other statins, its hydrophilic properties prevents widespread tissue distribution. Conversely, other statins; particularly cerivastatin, are highly lipophilic. The hepatoselectivity of statins contribute to their efficient pharmacodynamics activity given that cholesterol is synthesized in the liver, this hepatoselectivity is mainly attributed to their physicochemical properties; particularly, their solubility properties.

**Diversity of statin pharmacodynamics**

Currently available statins have different hydrophilic/lipophilic properties, thereby, having different inhibition efficacy for extra-hepatic HMG-CoA reductase enzyme.

The lipid bilayer of the cellular membrane prevents hydrophilic statins from passage through the cellular membranes of extrahepatic cells. Conversely, lipophilic affinity of lipophilic statins encourages their penetration into hepatic and extrahepatic cells. This property of lipophilic statins determine the supratherapeutic effects achieved by some statins in extrahepatic organs. These include, inhibition of synthesis of dolichol, ubiquinone (CoQ10), farnesylated proteins, and heme A. Lipophilic statins attenuate the myocardial ATP production further worsening the affected the ischemic region. In contrast to pravastatin (hydrophilic statin), simvastatin (lipophilic statin) has increased the myocardial stunning and worsen reperfusion of the ischemic region. Similarly, fluvastatin and atorvastatin attenuate myocardial reperfusion of affected segment and enhance myocardia staggering, however, similar effects were not reported in dogs treated by pravastatin (hydrophilic statins). Desp. of greater tissue penetration of lipophilic statins compared to hydrophilic statins; the clinical studies have not reported a great difference between the members of statins. Additionally, it has been demonstrated that hydrophilic and lipophilic statin increase NO production and isoprenylation by endothelial cells and reducing the infarct size and protecting the myocardium from ischemia-reperfusion injury; through lipid-lowering-independent mechanism. These findings have complicated the picture of selection of weather hydrophilic or lipophilic statins is better for patients with cardiovascular diseases. Moreover, Statins lower serum cholesterol level and inflammatory cell counts in plaques (e.g. macrophage); stabilising plaques from ruptures. Nevertheless, when plaque rupture occurs, cardiac events in patients on lipophilic statin exacerbated leading to ischaemia.

**Table 1. Pharmacokinetics of statins.**

<table>
<thead>
<tr>
<th>Dosing Time</th>
<th>Atorvastatin</th>
<th>Fluvastatin</th>
<th>Lovastatin</th>
<th>Pitavastatin</th>
<th>Pravastatin</th>
<th>Rosuvastatin</th>
<th>Simvastatin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prodrug</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Bioavailability</td>
<td>12%</td>
<td>9-50%</td>
<td>5%</td>
<td>51%</td>
<td>18%</td>
<td>20%</td>
<td>5%</td>
</tr>
<tr>
<td>Half-Life</td>
<td>14h</td>
<td>2.3h</td>
<td>3h</td>
<td>12h</td>
<td>2h</td>
<td>19h</td>
<td>3h</td>
</tr>
<tr>
<td>Lipophilicity</td>
<td>Lipophilic</td>
<td>Lipophilic</td>
<td>Lipophilic</td>
<td>Lipophilic</td>
<td>Hydrophilic</td>
<td>Hydrophilic</td>
<td>Lipophilic</td>
</tr>
<tr>
<td>Metabolites</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

**Metabolism**

Statins are mainly metabolized by cytochrome P450 enzyme; more precisely CYP3A4 isoenzyme play the greatest role in statin metabolism, the hypolipidaemic efficacy is partially related to the active metabolites; 2-hydroxyatorvastatin or 4-hydroxyatorvastatin for atorvastatin while for simvastatin the metabolites are hydroxysimvastatin, hydroxymethylsimvastatin, simvastatin, atorvastatin, and pitavastatin and rosuvastatin were only slightly metabolized by CYP450 isoenzyme. Oxidative metabolism by CYP 450 isoenzyme is the chief pathway for lipophilic statins, moreover, muscular toxicity is more prominent with those statins which undergo metabolism by CYP450 isoenzyme, which is most often related to drug interaction due to inhibition of CYP450 (notably the CYP3A4 system).

**Elimination**

The major route of elimination of most statin metabolites is bile, therefore liver failure is a contributing factor for statin induced adverse effects especially myopathy. Pravastatin excreted unchanged by liver and kidney, and liver dysfunction have slight effect on pharmacokinetic properties. Similarly, rosuvastatin mainly eliminated unchanged by liver and kidney, and liver dysfunction have no effects on its pharmacokinetic properties.
comparing the effects of hydrophilic statins versus lipophilic statin; at various time-points, data confirmed that there were a non-significant difference between statins.

A study conducted by Sakamoto et al., 2007; comparing the effects of hydrophilic statins (rosuvastatin and pravastatin) versus lipophilic statin (atorvastatin and simvastatin). After 2 years of initiation of therapy, the results showed that the Lipophilic Statin group showed a 2-fold reduction of LDL-C as compared with that of hydrophilic statins. A study conducted by Jones et al., 2003; using high doses of rosuvastatin, atorvastatin, simvastatin, and pravastatin. The study has compared lipid profile parameters. The results indicated that LDL reduction were best with rosuvastatin and least with atorvastatin. Similarly, HDL elevation was best with rosuvastatin and worst with atorvastatin. In a different study, conducted by Nicholls et al., 2010; using a sequential doses of hydrophilic versus lipophilic hypolipidemic agents. The study has compared lipid profile measurements of a range of different doses of the statins with each other and other hypolipidemic agents. The study concluded a remarkable efficacy of hydrophilic statin over lipophilic one.

Conclusions
It has been confirmed that hydrophilic and lipophilic statins are different in many molecular aspects, including structure, mode of action, pharmacokinetic and pharmacodynamic properties. The present systematic review has focused on the comparison between published studies on hydrophilic versus lipophilic statins to detect the differences between these drugs regarding their hypolipidaemic efficacy, if any. Collected studies; confirm that hydrophilic statins show much better effect on overall lipid profile.

Acknowledgments
The authors are very grateful to the University of Mosul/College of Medicine and College of Pharmacy for their provided facilities, which helped to improve the quality of this work. Thanks, is also in order for the scientific committee in department of pharmacy and toxicology of the college of pharmacy/university of Mosul.

Conflict of interest
The authors declare no conflict of interest.

REFERENCES


